Predicting PD-L1 in Lung Adenocarcinoma Using 18F-FDG PET/CT Radiomic Features

被引:0
|
作者
Zhang, Huiyuan [1 ]
Meng, Xiangxi [2 ]
Wang, Zhe [3 ]
Zhou, Xin [2 ]
Liu, Yang [2 ]
Li, Nan [2 ]
机构
[1] Capital Med Univ, Beijing Chest Hosp, Beijing TB & Thorac Tumor Res Inst, Dept Nucl Med, Beijing 101149, Peoples R China
[2] Peking Univ, Minist Educ, Dept Nucl Med, Natl Med Prod Adm,Canc Hosp & Inst,Beijing Key Lab, 52 Fucheng Rd, Beijing 100142, Peoples R China
[3] Cent Res Inst, United Imaging Healthcare Grp, Shanghai 201900, Peoples R China
关键词
PD-L1; F-18] FDG; PET/CT; radiomics; lung adenocarcinoma; POSITRON-EMISSION-TOMOGRAPHY; CANCER; EXPRESSION; DOCETAXEL; INFORMATION; NIVOLUMAB; IMAGES;
D O I
10.3390/diagnostics15050543
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background/Objectives: This study aims to retrospectively analyze the clinical and imaging data of 101 patients with lung adenocarcinoma who underwent [F-18]FDG PET/CT examination and were pathologically confirmed in the Department of Nuclear Medicine at Peking University Cancer Hospital. This study explores the predictive value and important features of [F-18]FDG PET/CT radiomics for PD-L1 expression levels in lung adenocarcinoma patients, assisting in screening patients who may benefit from immunotherapy. Methods: 101 patients with histologically confirmed lung adenocarcinoma who received pre-treatment [F-18] FDG PET/CT were included. Among them, 44 patients were determined to be PD-L1 positive and 57 patients were determined to be PD-L1 negative based on immunohistochemical assays. Clinical data, PET/CT radiomics parameters, conventional metabolic parameters, and observed CT characteristics were included in the modeling. Random Forest was used in feature denoising, while Forward Stepwise Regression and the Least Absolute Shrinkage and Selection Operator were used in feature selection. Models based on Tree, Discriminant, Logistic Regression, and Support Vector Machine were trained and evaluatedto explore the value of clinical data, PET/CT radiomics parameters, conventional metabolic parameters, and observed CT characteristics. Results: All models showed some predictive ability in distinguishing PD-L1 positive from PD-L1 negative samples. Among the multimodal imaging, clinical data were incorporated into the models, with clinical stage and gender selected by Forward Stepwise Regression, while clinical stage, smoking history, and gender were selected by LASSO. When incorporating clinical data and thin-section CT-derived images into the models, nodular type, spiculation, and CT Shape Flatness were selected by Forward Stepwise Regression, while nodular type and spiculation were selected by LASSO. When incorporating clinical data, PET/CT radiomics, observed CT characteristics, and conventional metabolic information. Forward Stepwise Regression selected TLGlean, MTV, nodule component, PET Shape Sphericity, while LASSO selected SULmax, MTV, nodular type, PET Shape Sphericity, and spiculation. Conclusions: The integration of clinical data, PET/CT radiomics, and conventional metabolic parameters effectively predicted PD-L1 expression, thereby assisting the selection of patients who would benefit from immunotherapy. Observed CT characteristics and conventional metabolic information play an important role in predicting PD-L1 expression levels.
引用
收藏
页数:13
相关论文
共 50 条
  • [41] Association Between PD-L1 Expression and Metabolic Activity on 18F-FDG PET/CT in Patients with Small-sized Lung Cancer
    Takada, Kazuki
    Toyokawa, Gouji
    Tagawa, Tetsuzo
    Kohashi, Kenichi
    Akamine, Takaki
    Takamori, Shinkichi
    Hirai, Fumihiko
    Shoji, Fumihiro
    Okamoto, Tatsuro
    Oda, Yoshinao
    Maehara, Yoshihiko
    ANTICANCER RESEARCH, 2017, 37 (12) : 7073 - 7082
  • [42] Differentiation Among Non-Small Cell Lung Cancer Subtypes Using Quantitative Radiomic Features of 18F-FDG PET/CT
    Sha, X.
    Gong, G.
    Qiu, Q.
    Yin, Y.
    MEDICAL PHYSICS, 2019, 46 (06) : E336 - E336
  • [43] Predicting the Efficacy of SBRT for Lung Cancer with 18F-FDG PET/CT Radiogenomics
    Chen, Kuifei
    Hou, Liqiao
    Chen, Meng
    Li, Shuling
    Shi, Yangyang
    Raynor, William Y.
    Yang, Haihua
    LIFE-BASEL, 2023, 13 (04):
  • [44] Predicting PD-L1 expression using [18F]FDG PET/CT in early stage non-small cell lung cancer (NSCLC)
    Hughes, D. J.
    Josephides, E.
    O'Shea, R.
    Manickavasagar, T.
    Horst, C.
    Hunter, S.
    Taniere, P.
    Nonaka, D.
    Spicer, J.
    Goh, V.
    Bille, A.
    Karapanagiotou, E. M.
    Cook, G.
    ANNALS OF ONCOLOGY, 2023, 34 : S741 - S741
  • [45] Predicting PD-L1 expression status in patients with non-small cell lung cancer using [18F]FDG PET/CT radiomics
    Zhao, Xiaoqian
    Zhao, Yan
    Zhang, Jingmian
    Zhang, Zhaoqi
    Liu, Lihua
    Zhao, Xinming
    EJNMMI RESEARCH, 2023, 13 (01)
  • [46] Predicting PD-L1 expression status in patients with non-small cell lung cancer using [18F]FDG PET/CT radiomics
    Xiaoqian Zhao
    Yan Zhao
    Jingmian Zhang
    Zhaoqi Zhang
    Lihua Liu
    Xinming Zhao
    EJNMMI Research, 13
  • [47] 18F-FDG PET/CT features in systemic mastocytosis
    Djelbani, S.
    Chandesris, M.
    Mekinian, A.
    Monsarrat, O.
    Pop, G.
    Durieu, I.
    Georgin-Lavialle, S.
    Grosbois, B.
    Eder, V.
    Hermine, O.
    Fain, O.
    Soussan, M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2013, 40 : S375 - S375
  • [48] 18F-FDG PET/CT features of thoracolumbar tuberculosis
    Tan Beibei
    JOURNAL OF NUCLEAR MEDICINE, 2018, 59
  • [49] Interchangeability of radiomic features between [18F]-FDG PET/CT and [18F]-FDG PET/MR
    Diem Vuong
    Tanadini-Lang, Stephanie
    Huellner, Martin W.
    Veit-Haibach, Patrick
    Unkelbach, Jan
    Andratschke, Nicolaus
    Kraft, Johannes
    Guckenberger, Matthias
    Bogowicz, Marta
    MEDICAL PHYSICS, 2019, 46 (04) : 1677 - 1685
  • [50] Robustness study on radiomic features in [18F]-FDG PET/CT and [18F]-FDG PET/MR
    Vuong, D.
    Bogowicz, M.
    Huellner, M.
    Veit-Haibach, P.
    Andratschke, N.
    Unkelbach, J.
    Guckenberger, M.
    Tanadini-Lang, S.
    RADIOTHERAPY AND ONCOLOGY, 2018, 127 : S1159 - S1159